MRNA

As of 2026-10-26, MRNA scores 37out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. MRNA trades at $198.85, 43% above the band ceiling.

MRNA scores 37 out of 100 on QNTM's five-factor model — a low-conviction reading — at 37 the factor profile is among the weaker names in the universe. Its strongest factor is momentum at 66 (strong), where price trend and relative strength are working in its favor, followed by volume at 55. The weakest is quality at 16, where earnings-quality metrics lag. Among Healthcare stocks it sits in the lower 12% of Healthcare names by composite.

On valuation, MRNA is priced near the top of its recent range — the rich end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 37. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on MRNA, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where MRNA sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for MRNA runs $66.99–$139.12. Current price $198.85 sits 43% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.